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Abstract
Objective—Autologous bone marrow (BM) cells with a faulty gene corrected by gene targeting
could provide a powerful therapeutic option for patients with genetic blood diseases. Achieving
this goal is hindered by the low abundance of therapeutically useful BM cells and the difficulty of
maintaining them in tissue culture long enough for completing gene targeting without them
differentiating. Our objective was to devise a simple long-term culture system, using unfractioned
BM cells, that maintains and expands therapeutically useful cells for ≥4 weeks.
Materials and Methods—From 2 to 60 million BM cells from wild-type (WT) mice, or from
mice carrying a truncated erythropoietin receptor transgene (tEpoR-tg), were plated with or
without irradiated fetal-liver derived AFT024 stromal cells in 25 cm2 culture flasks. Four-week
cultured cells were analyzed and transplanted into sublethally irradiated thalassemic mice (1
million cells / mouse).
Results—After 4 weeks, the cultures with AFT024 cells had extensive “cobblestone” areas.
Optimum expansion of Sca-1 positive cells was 5.5-fold with 20 × 106 WT cells/flask and 27-fold
with 2 × 106 tEpoR-tg cells. More than 85% of thalassemic mice transplanted with either type of
cells had almost complete reversal of their thalassemic phenotype for at least 6 months, including
blood smear dysmorphology, reticulocytosis, high ferritin plasma levels and hepatic/renal
hemosiderosis.
Conclusion—When plated at high cell densities on irradiated fetal-liver derived stromal cells,
BM cells from WT mice maintain their therapeutic potential for 4 weeks in culture, which is
sufficient time for correction of a faulty gene by targeting.
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Introduction
Hematopoietic stem cells (HSC) have been the subject of intensive study since their
identification in the 1960s by Till and McCulloch [1]. HSC are capable of self-renewal and
of differentiation to all blood cell types. Indeed, bone marrow repopulation has been
demonstrated with a single mouse HSC [2,3]. However, maintaining and expanding HSC in
culture for extended times without differentiation is difficult, although much progress has
been achieved by the use of culture systems based on the long-term bone marrow cell
culture (LTBMC) system described by Dexter et al. [4]. For example, we have shown that
mouse bone marrow (BM) cells can be maintained in culture for greatly extended periods of
time, and their proliferation enhanced if a truncated erythropoietin receptor (tEpoR) under
the control of a β actin promoter is introduced into the genome of the donor mice [5]. Others
have achieved comparable long-term cultures of murine BM cells by including a Hox B4
transgene [6], or by the use of a cocktail of growth factors [7]. In the current study we
describe a simple procedure, using unfractionated BM cells plated at high cell density on a
feeder layer of irradiated fetal-liver derived stromal cells (AFT024), that allows survival of
therapeutically-competent cells for ≥ 4 weeks, which is sufficient time for achieving gene
targeting. [Stromal-based culture was chosen, as opposed to a liquid-based culture [7],
because electroporated cells survive better in stromal cultures than in liquid cultures, and
because fewer technical difficulties are encountered in the subsequent tests for targeted gene
correction using color gene markers [8], or PCR screening, or protein expression, etc.] We
demonstrate that the phenotype of severely thalassemic mice becomes close to normal for at
least 6 months after receiving BM cells from wild-type or tEpoR transgenic donors that have
been cultured for ≥4 weeks under our conditions.
Materials and Methods
Long-term BM culture
BM cells were harvested by flushing femora and tibiae with phosphate-buffered saline
(PBS) containing 2% heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals,
Norcross, GA) (Flow buffer). Clumps of BM tissue were gently dispersed using an 18 G
needle with 10mL of a syringe, then centrifuged at 1,200 rpm (~450g) for 5 min and
resuspended with ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2-EDTA,
pH 7.4) to lyse red blood cells (5mL / mouse) for 5 min at room temperature. The lysis
reaction was stopped by adding an equal volume of Flow buffer and washed by centrifuging.
The pellet was resuspended with LTBMC medium containing 20% horse serum
(STEMCELL Technologies Inc., Vancouver, Canada), 10−6 M Hydrocortisone (Phizer Inc.,
NY), 2mM L-Glutamine and 100 U/ml penicillin/100 μg/ml streptomycin in Iscove's
modified Dulvecco's medium (IMDM; GIBCO, Grand Island, NY), and counted the cell
number. To test the effects of cell density on cell proliferation, 2, 6.3, and 20 M tEpoR-tg
BM cells and 2, 6.3, 20 and 60 M wild-type BM cells were plated separately onto irradiated
AFT024 feeder cells with LTBMC medium (5 mL / 25 cm2 flask) (plus 2 units EPO/mL for
the tEpoR-tg cultures) at 33 °C, 5% CO2 in a humid atmosphere for 4 weeks. Half of the
LTBMC medium was exchanged twice per week.
The murine fetal liver stromal cell line, AFT024 (a kind gift from IR Lemischka, Princeton
University, Princeton, NJ) was maintained in high-glucose Dulbecco's Modified Eagle's
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Medium (DMEM; GIBCO) supplemented with 15% FBS, 2mM L-Glutamine and 100 U/ml
penicillin/100 μg/ml streptomycin in a 75 cm2 flask (Falcon Plastics, Oxnard, CA) coated
with 0.3% porcine gelatin (Sigma-Aldrich, St. Louis, MO) and maintained at 37°C. The
stromal cells were passaged by 0.05% trypsin/EDTA (Invitrogen, Carlsbad, CA) when
approximately 80% confluent and plated 1:5 to new gelatin-coated flasks. To prepare
stromal feeders for long-term BM cultures, the AFT024 cells were irradiated with a 3 Gy y-
ray (Gammacell 40, Best Theratronics Ltd, Ontario, Canada) and plated at a density of 1.1
million (M) cells per 25 cm2 on gelatin coated flasks.
Transplantation assays
Four-week cultured BM cells were detached from flasks by 0.05% trypsin/EDTA for 5 min,
and dispersed with the LTBMC medium and filtered at 40 μm. After centrifuging, the
medium was changed to Flow buffer. The cells were transplanted into sublethally irradiated
(7.5 Gy) C654T ß-globin mutated mice (1.0 × 106 cells / mouse) through the retro-orbital
sinus under anesthesia. The transplanted mice were maintained in microisolator cages with
autoclaved food and acidified sterile water supplemented with neomycin sulfate for the first
2 weeks after transplant.
Animals
Male tEpoR-tg mice and wild-type (WT) GFP-tg mice, both on a C57BL/6J background,
were used as BM donors. The tEpoR-tg mice have a truncated erythropoietin receptor
transgene, driven by a human ß-actin promoter, inserted into the Hprt locus on the X
chromosome [5]. The WT GFP-tg mice have an hrGFP transgene (Stratagene, La Jolla, CA)
with a nuclear localization signal, also driven by the human ß-actin promoter and also
inserted into the Hprt locus; the hrGFP transgene is flanked by two copies of a prototypic
vertebrate insulator from the chicken (β-globin locus [9]. The recipient mice were C654T ß-
globin mutated females (ß-thal) on a C57BL/6J background that have a mutant human ß-
globin gene driven by the natural human ß-globin promoter in place of the normal mouse
adult ß-globin genes [10]. The animals were maintained in microisolator cages with
irradiated standard mouse chow in the animal facility at the University of North Carolina
(Chapel Hill, NC) in accordance with Institutional Animal Care and Use Committee
standards. All experimental mice were approximately 4 to 5 months old.
Flow cytometry analysis
Fresh BM cells and 4-week cultured BM cells were obtained as described above. Peripheral
blood samples were collected from retro-orbital sinus under anesthesia and were lysed in
ACK lysis buffer and washed twice with the Flow buffer. One million cells were incubated
with 5% Fc-block (CD16/CD332) supernatant for 5 min on ice before staining. Appropriate
amounts (0.03-0.05 μg / 1 million cells) of the following antibodies were added: Sca-1–-
APC (Biolegend, San Diego, CA); Lineage markers including 5 kinds of antibodies:
CD45R/B200–phycoerythrin (PE); CD3ε–PE, TER119–PE, Ly-6C (Gr-1)–PE and CD11b–
PE (All from BD Biosciences, San Diego, CA); c-Kit (CD117)–Biotin (eBioscience, San
Diego, CA). The cells were incubated on ice in the dark for 15-20 min, and then washed
twice with Flow buffer. As secondary antibody reaction, 0.25 μg of Streptavidin–PE-Cy5.5
(eBioscience) was added and incubated with Flow buffer on ice in the dark for 5 to 10 min.
After washing twice with Flow buffer, cells were resuspended with 300μL of Flow buffer.
Samples were analyzed using a CyAn ADP Flow Cytometer (Beckman Coulter Inc.,
Fullerton, CA) and Summit™ Software ver. 4.3 (DakoCytomation, Glostrup, Denmark). A
minimum of 50,000 events was acquired for each sample.
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Blood smears, made from 1.8μL of blood collected in heparinized microhematocrit tubes,
were air dried and stained with Wright stain or new methylene blue for reticulocyte
counting. The reticulocytes were observed using the x100 oil-immersion lens and were
counted the percentage per 1000 red blood cells.
Statistics
Results of experimental points from different experiments are reported as the mean, standard
error of the mean (SEM). Significance levels were determined by either paired or non-paired
Student's t-test analysis as indicated. For multiple comparisons from different experimental
conditions, the statistical significance was evaluated using post-hoc analysis with Scheffέ's
test. The nonparametric Mann-Whitney U test was used for analyzing data from blood
smears (Fig. 3C).
Results
Long-term Dexter-type cultures of BM cells from tEpoR-tg and wild-type mice BM cells
from mice carrying a tEpoR transgene (tEpoR-tg) survive for up to 140 days and increase in
number in long-term bone marrow cell cultures (LTBMC) when supplemented with
erythropoietin (EPO) [5]. Cobblestone areas become predominant in these long term
cultures as they progress. Comparable cultures with wild-type BM cells, with or without
EPO, have no detectable cobblestone areas after 80 days. For our present experiments,
aimed at finding conditions enabling productive LTBMC with wild-type BM cells, we
therefore used irradiated fetal liver derived AFT024 cells [11] as stromal feeder cells
because of their ability to facilitate the growth of bone marrow cells. We also chose to avoid
EPO supplementation in the WT BM cultures because of its tendency to induce terminal
differentiation.
Effects of BM Cell Numbers
We first determined the effects of increasing the numbers of cells per culture flask. Our
investigation of this variable was guided by the thought that higher cell densities might
encourage the development of cell clusters able to provide a micro-environment for stem
cell proliferation comparable to that in normal bone marrow. As summarized in Fig. 1A,
varying numbers (2, 6.3, 20 and 60 million) of BM cells, harvested from mice carrying the
tEpoR-tg or from WT mice, were plated on AFT024 feeder layers in 25 cm2 culture flasks
(plus 2 units EPO/mL for the tEpoR-tg cultures). Table 1 and Fig. 1B and 1C show clear and
marked differences between the results when the BM cells are from mice having the tEpoR
transgene compared with those from WT mice. When the numbers of input tEpoR-tg BM
cells were increased from 2 million (M) to 20M per flask, the fold increase in total cell
number after 4 weeks decreased from 2.8-fold to 0.34-fold while the fold increase in Sca-1
(+) cells fell from 28- to 2.4-fold. In contrast, with WT BM cells, when input numbers were
increased from 2M to 20M, the fold increase in the total cell number remained essentially
constant at ~ 0.5-fold while the fold increase in Sca1(+) cells increased from 1.3- to 5.5-fold.
At 60M input of WT BM cells, the fold increase in total cell number decreased to 0.21-fold,
while the fold increase in Sca1(+) cells decreased to 1.7-fold. Thus the optimum input
number for tEpoR-tg BM cells in our system is 2M per flask. Yet it is 20M for WT BM
cells. Despite these differences the end point cultures are very similar; both have extensive
“cobblestone” areas (Fig. 1D). Some flow data for single experiments (Fig. 1E and 1F) show
that the percentages of Sca-1 (+) cells (outlined in blue) and Sca-1 (+)/c-Kit (+)/Lineage (−)
cells (SKL, outlined in black) increase during the culture period; see also Table 1. [Deletion
Here] We conclude that culturing tEpoR-tg BM cells at higher densities decreases the fold
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expansion of Sca1 (+) cells, whereas culturing WT cells at higher densities increases the fold
expansion, with an optimum at 20M input cells per flask.
Effects of Feeder Cell Numbers
We next explored the influence of the numbers of AFT024 feeder cells on the survival of
BM cells after long-term culture (Fig. 2A). We seeded various densities of the AFT024
feeder cells into flasks and plated 20M WT BM cells in each. We used 1.1 M cells per 25
cm2 flask as a baseline (1×), as this is the approximate number of cells found in a confluent
flask (Fig. 2B). Half of this is designated as 0.5× and so forth. The effect of AFT024 feeder
density on the ability of BM cells to expand is illustrated in Fig. 2C. We found that the total
number of BM cells per 20 M input cells increased progressively as the feeder cells in the
flask were increased up to 2×. At higher densities the feeder layer rolled over, and most of
the BM cells were lost. The numbers of Sca-1 (+) cells in the flasks are affected by the
density of the feeder layer in the same manner as the total number (Fig. 2C, right panel). We
therefore chose a standard density of 1.1 M AFT024 feeder cells per 25 cm2 flask for all
subsequent cultures in this study.
Therapeutic benefits in mutant βC654T mice transplanted with 4-week cultured BM cells
To determine the therapeutic potential of the cells obtained after 4 weeks in culture, the
cultures were disaggregated, and the unfractionated dispersed cells were transplanted into
βC654T thalassemic (ß-thal) mice [10] (1M cells / mouse) that had been irradiated with a
sublethal dose of 7.5 Gy. This mouse has one copy of chromosome 7 with the normal mouse
ß globin genes, and one copy of chromosome 7 in which both adult ß globin genes (ßmajor
and ßminor) have been replaced by a human ß-globin gene harboring a splicing mutation.
Mice heterozygous for this mutant ß globin gene manifest classic signs of ß thalassemia
intermedia, namely anisocytosis, poikilocytosis, and target cells in the peripheral blood
smear. The transplanted mice were analyzed every two weeks to observe the erythrocyte
morphology and the number of reticulocytes by blood smears. Improvement in the
morphology was noted four to six weeks later, as shown in Fig. 3B. In order to perform
semi-quantitative analyses of blood smears, we generated an index of five standard mixes of
blood from WT with ß-thal mice (Fig. 3C). Cells cultured for 4 weeks in the optimal culture
conditions for both tEpoR-tg and WT cells were transplanted into six or seven sublethally
irradiated ß-thal mice (Fig. 3A). All transplanted mice lived to 6 months post-transplant, and
significant improvements were seen in erythrocyte morphology, e.g. the index increased
from 1 to 4-5 by 2 months post-transplant in all mice (p < 0.01, pre-transplant versus 1
month post-transplant). The percentage of reticulocytes also decreased favorably in all
transplanted mice, to less than 1% from a starting value of approximately 3.7% (the average
in ß-thal mice) (Fig. 3D). This improvement in reticulocyte percentage persisted for at least
6 months in all mice. We also have evidence that nucleated myeloid cells derived from the
donor are present in the recipient (Supplementary Fig. E1).
Lymphoid differentiation from 4-week cultured BM cells in vivo
All the WT mice that we used as donors carry a ubiquitously expressed GFP transgene [9],
see Materials and Methods, as a marker enabling the recognition of donor cells in
thalassemic mice receiving a transplantation. To make this distinction, we performed flow
analysis on peripheral blood cells obtained from transplanted ß-thal mice 5 to 6 months post-
transplant, and the cells were measured for GFP (+) cells as well as for the B-cell marker
CD19, and the T-cell marker CD3 epsilon (CD3ε), which recognizes CD3ε chains in the T-
cell CD3 receptor complex. The percentages of CD19 (+) cells recovered were 17% from
transplanted cells (CD19+GFP+, outlined in blue) and 45% from host cells (CD19+GFP−,
see Fig. 3E). As for T cells, 7% were derived from transplanted cells (CD3ε+GFP+, outlined
in blue) and 16% were derived from the host (CD3ε+GFP−)(Fig. 3F). The culture conditions
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used in this study do not support long term survival or proliferation of lymphoid cells (data
not shown). Accordingly, this result suggests that the transplanted cells may include
common lymphoid progenitors (CLPs) that give rise to T and B cells. Additionally, 4% of
the Sca-1 (+) cells in peripheral blood were derived from the transplanted cultured cells
(Sca-1+GFP+, outlined in blue) and 8% were from host cells (Sca-1+GFP−, see Fig. 3G).
The presence of mixed chimerism in the lymphoid series is probably a function of the
sublethal dose of radiation employed.
Post-Transplant Improvement in Organ Function
ß-thal mice manifest phenotypes similar to those seen in human ß thalassemia intermedia,
including iron deposition, splenomegaly and ventricular hypertrophy. Some of these effects
were reversed in ß-thal mice transplanted with 4-week cultured BM cells from tEpoR-tg or
WT mice . Thus, no iron deposition was observed in all 7 mice receiving tEpoR-tg cells and
6 mice receiving WT cells (very low iron deposition was observed in one mouse kidney)
(Supplementary Fig. E2A). And at 6 months post transplant using the 4-week cultured BM
cells from the tEpoR-tg mice, the ß-thal phenotype was found to be reversed in the
following specific areas; (1) the heart weight was reduced (p < 0.01) (left histogram in
Supplementary Fig. E3A). (2) Left ventricular end-diastolic internal dimension (LVID) was
reduced in transplanted mice (p < 0.05) to levels > indistinguishable from WT (right
histogram in Supplementary Fig. E3A). (3) spleen size, which is more than 3 times larger in
ß-thal mice than in normal mice, was reduced (p < 0.05) to a size indistinguishable from
control (Supplementary Fig. E3B). (4) Plasma ferritin levels were improved (p < 0.01) from
nearly three times the control mouse level to approximately the same level as the control
mice (left histogram in Supplementary Fig. E3C). (5) Hematocrit, hemoglobin and leukocyte
value also improved (Supplementary Fig. E3C). These results demonstrate that
transplantation of 4-week cultured BM cells can reverse the pathologic phenotype of ß
thalassemia intermedia in this murine model.
Discussion
In the experiments presented, we have demonstrated that BM cells with normal murine (β-
globin genes from mice with or without a tEpoR transgene, when transplanted after four
weeks in culture at high cell densities in the presence of irradiated AFT024 stromal cells,
can provide therapeutic benefits in thalassemic mice. After transplantation, the morphology
of erythrocytes in the recipient mice improved very substantially and the reticulocyte
number was normalized. The transplanted cells were also shown to have differentiated to
lymphocytes. The therapeutic benefits in thalassemic mice resulting from transplanting our
4-week cultured BM cells persisted for at least 6 months, demonstrating that the cultures
include long term repopulating cells. Because we did not carry out serial transplantation
tests, we cannot conclude that the 4-week cultures include “true” hematopoietic stem cells.
But we can conclude that our simple culture system enabled us to reach our objective of
maintaining therapeutically useful wild-type BM cells for 4 weeks in culture, which is
sufficient time for carrying out corrective gene targeting using suitably designed DNA
constructs, such as those described by us previously [8].
We used a novel high density culture system for our experiments with the aim of replicating
the crowded marrow micro-environment as much as possible in ex vivo culture. We used
unfractionated BM cells rather than purified stem cells with the aim of providing as many
adjunct stromal cells as possible to support the stem cells. Even so, in order to achieve
longer survival times of the BM cells, we found it necessary to include irradiated AFT024
stromal cells in the cultures. A number of studies describing co-culture with AFT024
stromal cells have been published [11,12]. A potential problem is associated with the use of
the immortal liver-derived AFT024 cells, namely the ability of bone-marrow derived cells to
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fuse with other cells [13]. If a donor BM cell fused with an AFT024 stromal cell (an
immortalized cell line), it is possible that the fused cell could proliferate in an uncontrolled,
potentially malignant manner. However, we have not seen cells of this type in our cultures,
or any abnormal cell growth in the mice receiving our cultured cells. Nevertheless, in order
to provide a safer therapeutic option, our future studies will include attempts to obtain a
source of stromal cells other than AFT024 . For example, one might envision performing
gene correction procedures to reverse genetic defects in newborns using unfractionated
nucleated cells from umbilical cord blood cultured at high cell density on a HUVEC type
feeder layer prepared from umbilical cord endothelial cells [14] or from amniotic
mesenchymal cells [15].
Some comment is required on the considerable difference in optimal plating density that we
have observed between bone marrow cells from WT mice and those from mice carrying the
tEpoR-tg. As indicated above, we suggest that the WT cells require plating at a high density
in order for the development of hematopoietically beneficial niches and/or sources of
hematopoietic factors that can stimulate the survival and expansion of therapeutically useful
cells. However, at this (high) cell-density addition of EPO causes the feeder cell layer to curl
up. For this reason, and because EPO tends to promote differentiation of WT BM cells, we
did not include it in the WT cultures. In contrast, therapeutically useful cells in mice
carrying the tEpoR-tg respond to EPO by dividing. Consequently, we add it to their medium,
and they readily increase in number even at low cell densities. At high cell densities the
tEpoR-tg cultures, like the WT cultures, are adversely affected by EPO.
In summary, as one of many steps towards developing a practical gene targeted approach for
the treatment of inherited hematologic and immunologic diseases, we have demonstrated
that unfractionated BM cells, plated at high cell densities on irradiated fetal-liver derived
stromal cells, maintain their therapeutic potential for 4 weeks in culture, a window of time
sufficient for correcting a faulty gene by targeting.
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Figure 1. Analyzing 4-week cultured BM cells from tEpoR-tg and wild-type mice
(A) Experimental overview. Bone Marrow (BM) cells were harvested from tEpoR-tg and
wild-type (WT) mice and plated at different cell densities on stromal feeders. Erythropoietin
(EPO) was added to the tEpoR-tg cell flask. The cultured cells were analyzed at 4 weeks.
(B) and (C) Fold increase of total cell number (B) and Sca-1 (+) cell number (C) at 4 weeks
relative to the initial cell number. Varying numbers (2, 6.3, 20 and 60 million) of BM cells
were seeded initially and counted after 4 weeks. Blue highlighted line indicates one fold
increase. A student's t-test was used to assess statistical significance between tEpoR-tg and
WT cells. (*p < 0.01; †p < 0.05). (D) Cobblestone area from tEpoR-tg (left) and WT (right)
cells at week 4. The initial cell numbers are shown. Bar represents 50 μm. (E) and (F) Flow
cytometry analyses of cells cultured 4-weeks (right two images) compared with the fresh
BM (left two images) from tEpoR-tg (E) and WT (F) mice. Analyses of Sca-1/Lineage
markers are shown in the upper two figures, and Sca-1/c-Kit/Lineage negative (SKL) are
shown in the lower two figures.
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Figure 2. Effects of Feeder Cell Numbers
(A) Various densities (0 to 4-fold (×) versus typical confluence (1 ×)) of AFT024 stromal
cells were tested with 20 million (M) BM cells from WT (GFP) mice in 25 cm2 flasks. (B)
Typical density (1 ×) of AFT024 feeder cells was used in this study for all other
experiments. Scale Bar: 100μm. (C) The total number of cells (in the left panel) attached to
the 25 cm2 flask was counted at Week 4. The densities of 0.5× to 2× of the feeder layer
maintained higher numbers of cells. In flasks containing higher numbers of feeder cells (4×
density, 4.4M cells/25 cm2 flask), the feeder layer often detached from the bottom of the
flask and rolled over with the bone marrow cells, causing a decrease in the final cell number
(denoted by a dashed line). The number of Sca-1 (+) cells was shown in the same manner as
the total number in the right panel.
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Figure 3. Therapeutic benefits in β-thal mice transplanted with 4-week cultured BM cells from
tEpoR-tg and WT mice
(A) Experimental overview. BM cells were harvested by the same manner as shown Fig. 1A.
The respective optimal culture conditions, as described in Fig. 1, were used for both tEpoR-
tg and WT cells. One million unfractionated cells were transplanted to an irradiated β-thal
mice after 4-weeks in culture. (B) Peripheral blood smears pre- and post-transplantation.
Smears from pre-transplant (blood smear from a β-thal mouse) (left), 4 to 6 weeks post
transplant (middle two pictures) and WT (non-transplanted) control mice (right). (C)
Improvement of erythrocyte morphology 6 to 7 months post-transplant. Transplant-recipient
mice were tracked with tEpoR-tg (upper) and WT (lower) cells, respectively. A Mann-
Whitney U test was used to assess statistical significance between Month 0 and 1 within the
same donor mice. (* p <0.01; tEpoR-tg, n = 7; WT, n = 6;) (D) Improvement of reticulocyte
amount in the peripheral blood 6 to 7 months post transplant. The same mice analyzed in
Fig. 1C were analyzed here. The normal reticulocyte percentage is less-than 1%, and
emphasized by a blue horizontal line. (E), (F) and (G) Flow analysis of peripheral blood
from the recipient mice transplanted with WT (GFP) cells. CD19 for B cells (E), CD3ε for T
cells (F) and Sca-1 (G) were analyzed 5 to 6 months post-transplant by GFP-positivity. The
blue outline emphasizes both GFP and the marker (+) cells.
Hatada et al. Page 11





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Exp Hematol. Author manuscript; available in PMC 2012 March 1.
